company background image
DVLA

Darya-Varia Laboratoria IDX:DVLA Stock Report

Last Price

Rp2.44k

Market Cap

Rp2.7t

7D

-0.4%

1Y

5.6%

Updated

19 May, 2022

Data

Company Financials
DVLA fundamental analysis
Snowflake Score
Valuation5/6
Future Growth0/6
Past Performance2/6
Financial Health5/6
Dividends5/6

DVLA Stock Overview

PT Darya-Varia Laboratoria Tbk engages in the manufacture and trading of pharmaceutical products and cosmetics in Indonesia and internationally.

Darya-Varia Laboratoria Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Darya-Varia Laboratoria
Historical stock prices
Current Share PriceRp2,440.00
52 Week HighRp3,400.00
52 Week LowRp2,250.00
Beta-0.0098
1 Month Change-11.27%
3 Month Change-18.12%
1 Year Change5.63%
3 Year Change8.93%
5 Year Change16.75%
Change since IPO187.06%

Recent News & Updates

Shareholder Returns

DVLAID PharmaceuticalsID Market
7D-0.4%-0.4%-1.0%
1Y5.6%1.5%18.2%

Return vs Industry: DVLA exceeded the ID Pharmaceuticals industry which returned 1.5% over the past year.

Return vs Market: DVLA underperformed the ID Market which returned 18.2% over the past year.

Price Volatility

Is DVLA's price volatile compared to industry and market?
DVLA volatility
DVLA Average Weekly Movement3.7%
Pharmaceuticals Industry Average Movement3.7%
Market Average Movement6.3%
10% most volatile stocks in ID Market12.2%
10% least volatile stocks in ID Market3.0%

Stable Share Price: DVLA is less volatile than 75% of ID stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: DVLA's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19761,239Jose Romanahttps://www.darya-varia.com

PT Darya-Varia Laboratoria Tbk engages in the manufacture and trading of pharmaceutical products and cosmetics in Indonesia and internationally. It operates in three segments: Prescription Drugs, Consumer Health Products, and Export and Toll Manufacturing Services. It provides various prescription and consumer health products in antibiotic, antiparasit, antiseptic, anti-fungal, cough and cold, cardiology, central nervous system, gastro-hepatology, somatic, vitamin and food supplement, women healthcare, ear healthcare, and derma medic areas.

Darya-Varia Laboratoria Fundamentals Summary

How do Darya-Varia Laboratoria's earnings and revenue compare to its market cap?
DVLA fundamental statistics
Market CapRp2.73t
Earnings (TTM)Rp146.73b
Revenue (TTM)Rp1.90t

18.6x

P/E Ratio

1.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
DVLA income statement (TTM)
RevenueRp1.90t
Cost of RevenueRp905.76b
Gross ProfitRp995.13b
Other ExpensesRp848.41b
EarningsRp146.73b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)131.01
Gross Margin52.35%
Net Profit Margin7.72%
Debt/Equity Ratio1.7%

How did DVLA perform over the long term?

See historical performance and comparison

Dividends

4.6%

Current Dividend Yield

85%

Payout Ratio

Valuation

Is Darya-Varia Laboratoria undervalued compared to its fair value and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: DVLA (IDR2440) is trading below our estimate of fair value (IDR12887.84)

Significantly Below Fair Value: DVLA is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: DVLA is good value based on its PE Ratio (18.6x) compared to the ID Pharmaceuticals industry average (20.9x).

PE vs Market: DVLA is good value based on its PE Ratio (18.6x) compared to the ID market (18.9x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate DVLA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: DVLA is good value based on its PB Ratio (2x) compared to the ID Pharmaceuticals industry average (2.4x).


Future Growth

How is Darya-Varia Laboratoria forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


15.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Darya-Varia Laboratoria has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Darya-Varia Laboratoria performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


3.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: DVLA has high quality earnings.

Growing Profit Margin: DVLA's current net profit margins (7.7%) are lower than last year (8.9%).


Past Earnings Growth Analysis

Earnings Trend: DVLA's earnings have grown by 3.9% per year over the past 5 years.

Accelerating Growth: DVLA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: DVLA had negative earnings growth (-9.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (12.8%).


Return on Equity

High ROE: DVLA's Return on Equity (10.6%) is considered low.


Financial Health

How is Darya-Varia Laboratoria's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: DVLA's short term assets (IDR1,526.7B) exceed its short term liabilities (IDR595.1B).

Long Term Liabilities: DVLA's short term assets (IDR1,526.7B) exceed its long term liabilities (IDR110.0B).


Debt to Equity History and Analysis

Debt Level: DVLA has more cash than its total debt.

Reducing Debt: Insufficient data to determine if DVLA's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: DVLA's debt is well covered by operating cash flow (1894.3%).

Interest Coverage: DVLA earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Darya-Varia Laboratoria current dividend yield, its reliability and sustainability?

Dividend Score

4/6

Dividend Score 4/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


4.59%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: DVLA's dividend (4.59%) is higher than the bottom 25% of dividend payers in the ID market (1.12%).

High Dividend: DVLA's dividend (4.59%) is in the top 25% of dividend payers in the ID market (4.1%)


Stability and Growth of Payments

Stable Dividend: DVLA's dividend payments have been volatile in the past 10 years.

Growing Dividend: DVLA's dividend payments have increased over the past 10 years.


Earnings Payout to Shareholders

Earnings Coverage: At its current payout ratio (85.5%), DVLA's payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its reasonably low cash payout ratio (35.8%), DVLA's dividend payments are well covered by cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

7.3yrs

Average board tenure


CEO

Jose Romana (59 yo)

1.58yrs

Tenure

Mr. Jose Sumpaico Romana has been President Director and Director at PT Darya-Varia Laboratoria Tbk since October 20, 2020. Mr. Romana served as Vice President Director and Director at PT Darya-Varia Labor...


Board Members

Experienced Board: DVLA's board of directors are considered experienced (7.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

PT Darya-Varia Laboratoria Tbk's employee growth, exchange listings and data sources


Key Information

  • Name: PT Darya-Varia Laboratoria Tbk
  • Ticker: DVLA
  • Exchange: IDX
  • Founded: 1976
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: Rp2.733t
  • Shares outstanding: 1.12b
  • Website: https://www.darya-varia.com

Number of Employees


Location

  • PT Darya-Varia Laboratoria Tbk
  • Tower C
  • South Quarter
  • Jakarta
  • Jakarta Raya
  • 12430
  • Indonesia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/19 00:00
End of Day Share Price2022/05/19 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.